
STERIS plc (STE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Steris Corporation is an American Irish-domiciled medical equipment company specializing in sterilization and surgical products for the US healthcare system.
| Revenue (TTM) | $6.04B |
| Gross Profit (TTM) | $2.68B |
| EBITDA | $1.64B |
| Operating Margin | 19.20% |
| Return on Equity | 11.40% |
| Return on Assets | 6.80% |
| Revenue/Share (TTM) | $61.61 |
| Book Value | $73.92 |
| Price-to-Book | 2.83 |
| Price-to-Sales (TTM) | 3.37 |
| EV/Revenue | 3.631 |
| EV/EBITDA | 13.36 |
| Quarterly Earnings Growth (YoY) | 14.00% |
| Quarterly Revenue Growth (YoY) | 7.30% |
| Shares Outstanding | $97.50M |
| Float | $97.08M |
| % Insiders | 0.31% |
| % Institutions | 100.95% |
Volatility is currently contracting

STERIS plc (STE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Steris (STE) reported earnings 30 days ago. What's next for the stock?

Dublin, Ireland, Sept. 01, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will participate in the Morgan Stanley Healthcare Conference in New York City on Tuesday, September 15, 2026.

STE is betting $600 million on a new chemistry center to boost capacity and efficiency, but higher spending and execution risks loom.

STE enters fiscal 2027 with solid growth, recurring healthcare demand and better margins, but tariffs and investment needs temper the valuation case.

STERIS plc (STE) Q1 2027 Earnings Call Transcript

STERIS beats fiscal Q1 earnings estimates as sales rise 7.3%, but a modest revenue miss sends shares 2.4% lower after hours.

Recent dividend hikes from DRH, STE, BCC, KWR and WHD highlight financially solid companies as investors seek stability in a mixed market.

DUBLIN, IRELAND, Aug. 05, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2027 first quarter ended June 30, 2026. Total revenue for the first quarter of fiscal 2027 increased 7% to $1.5 billion compared with $1.4 billion in the first quarter of fiscal 2026. Constant currency organic revenue growth was 6% in the first quarter.

• This Formulated Chemistries Center of Excellence will support sterilization and disinfection for the global Healthcare and Pharmaceutical industries
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on STE and any ticker you trade — then tracks every position and per-strategy win rate.